Summary by Moomoo AI
SeaStar Medical, a commercial stage medical technology company, reported a net loss of $4.5 million for the third quarter ended September 30, 2024, a decrease from the $7.2 million net loss in the same period the previous year. The basic and diluted net loss per share was $1.10, compared to $9.02 in 2023. The company's net losses for the nine months ended September 30, 2024, were $20.4 million, up from $16.8 million in the prior year. SeaStar Medical's revenue for the quarter was $68 thousand, stemming from the commercial sales of its pediatric Selective Cytopheretic Device (SCD), which received FDA approval under a Humanitarian Device Exemption in February 2024. The company also raised approximately $2.0 million through an At-the-Market offering after September 30, 2024. SeaStar Medical's research and development expenses increased...Show More